Help Therapeutics Achieves $25 Million Series C Funding

Help Therapeutics Achieves $25 Million Series C Funding

As the first company in China to develop and manufacture cell therapy using induced pluripotent stem cell (iPSC) technology, Help Therapeutics insists on focusing on the fields of heart failure and tumor immune diseases to develop general-purpose cell therapy products to meet clinical demand.

As of late, the iPSC therapeutics leading worldwide platform company – Help Therapeutics announced the completion of Series C financing of 25 great many dollars. This round of financing was driven by Ming Bioventures, trailed by Share Capital, Beisen Medical Fund, and Jolmo Capital, with extra help from our old investor Purple Bull Startups, and Hoyue Capital going about as the exclusive financial advisor for this round of financing. The financing will help the organization conduct and complete clinical trials of its completely independent intellectual property development pipeline, iPSC heart cell injection, and will start clinical studies of resistant cell treatment dependent on iPSC technology inside the following year.

The company’s founder, Dr. Wang Jiaxian, is a medical doctor from the University of Hong Kong and a postdoctoral fellow at Mount Sinai School of Medicine in the United States. During his time as a cardiologist, Dr. Wang became concerned that the population of heart failure patients in China has reached over 10 million, and there are about 3 million patients with severe heart failure waiting for heart transplants every year, but only about 600 people can find heart donor, a huge gap that has become a problem for the entire medical community. Dr. Wang chose to enter the field of iPSC cell therapy in 2010, convinced that iPSC technology is a groundbreaking technology for human medicine, and looking forward to saving heart failure patients through this innovative cutting-edge technology. After years of development, the company has developed several product pipelines based on iPSC technology, mastering advanced iPSC reprogramming technology while having the capability of large-scale automated production and cell quality inspection of iPSC drugs.

iPSC pipeline layout Break through the heart failure treatment dilemma

Help Therapeutics has laid out several R&D pipelines in the areas of heart failure and tumor immunity, among which iPSC technology therapy for the treatment of moderate to severe heart failure has entered several authoritative centers nationwide to conduct large-scale randomized controlled human clinical trials. Help Therapeutics has accumulated profound experience in the field of heart failure cell therapy: In 2020, Nature reported the world’s first human study of iPSC cells for end-stage heart failure conducted jointly by the company and Nanjing Drum Tower Hospital. Based on 24-month follow-up data from three patients in this clinical trial, the efficacy and safety of Help Therapeutics’s iPSC-derived cardiomyocyte drug for the treatment of severe heart failure were excellent.

The company has already obtained the first iPSC technology-based heart failure cell therapy clinical study filing from the National Health Care Commission in China, and is also actively preparing clinical registration filings for both the U.S. and China for its heart failure treatment pipeline. After clinical trials, this product is expected to be the first iPSC cell therapy drug for moderate to severe heart failure in China and the world, and its social and commercial value will be incalculable.

Artificial intelligence fully automated production line, the world’s first biopharmaceutical 4.0 era

With the development of the cell therapy industry, the quantity and quality of cell culture are in more refined and higher demand, both from the perspective of clinical demand and R&D exploration. The current manual culture of cell therapy products has long operation time, large variation between product batches, low batch culture capacity and other industry bottlenecks, and thus the cost and terminal selling price of cellular drugs remain high, and cannot really reach the majority of patients. Therefore, addressing the commercial mass production of cells has become central to the development of cell therapy companies.

Help Therapeutics is at the forefront of the world’s technology in terms of cell mass production and quality assurance. Its fully automated production line has reached the international leading position, improving the quality and stability of cellular products while significantly reducing production costs. The annual production capacity of a single production line can meet 100,000 doses, contributing to the popularization of cellular products. The company’s fully automated production pipeline was selected for the National “13th Five-Year Plan” Science and Technology Innovation Achievement Exhibition. Taking the responsibility of the country as our own

Help Therapeutics has the first induced pluripotent stem cell (iPSC) biospecimen bank authorized by the Ministry of Science and Technology for the preservation of human genetic resources in China. Entrusted by the National Human Genetic Resources Sharing Service Platform and as the only officially recognized iPSC rare disease cell bank in the National 14th Five-Year Plan (National Science and Technology Heritage Office [2021]-BC0022), Help Therapeutics carries the heavy responsibility of human genetic material and makes every effort to promote the role of China’s iPSC technology platform and rare disease research and development treatment. Help Therapeutics will provide high-quality and diversified biological samples to research institutions and enterprises, accelerate rare disease research and orphan drug development, and help the rapid development of iPSC cell industry.

Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Local COVID-19 cases have dropped significantly since last report |  News
Local COVID-19 cases have dropped significantly since last report | News
Please continue to follow current guidelines and any updates on COVID-19 from the CDC. Make sure to check ahead to learn what requirements may be in place for ...
Rising gasoline costs trouble Asia as inflation poses a challenge
Soybeans seen in king corn slump as inflation drives down U.S. crops
A smaller corn harvest could lift already elevated U.S. grain prices, keeping livestock feed costs up and raising the prospect of ongoing meat inflation. ...
Bank of America job cuts proposal is a roadmap for navigating higher costs
Bank of America job cuts proposal is a roadmap for navigating higher costs
“Bank of America is a big contrast to JPMorgan,” Mike Mayo, an analyst at Wells Fargo & Co., said in a phone interview. They’re “doing more with less.” ...
Chamber Recognizes  News Leaders at 2022 Awards Banquet |  News
Chamber Recognizes News Leaders at 2022 Awards Banquet | News
President’s Award for 2021 Small Biz of the Year: Krystyn and John Richardson of BOLD Multimedia Volunteer of the Year: Jim Wade, president of BancFirst ...
Acquisitions and investments made by Reliance Industries recently
Acquisitions and investments made by Reliance Industries recently
Reliance Retail Ventures acquired a 52 percent equity stake in Ritika Pvt Ltd that owns Ritu Kumar, Label Ritu Kumar, RI Ritu Kumar, aarké, and Ritu Kumar ...
Biden officials talking to Qatar about gas supplies to Europe
Biden officials talking to Qatar about gas supplies to Europe
Some European nations have expressed fears that punishing Russia with harsh sanctions over the Ukraine crisis could wind up damaging their economies and ...
Loudoun County Announces COVID-19 Testing Events in Purcellville |  News
Loudoun County Announces COVID-19 Testing Events in Purcellville | News
No COVID-19 vaccine will be available at the testing events. The testing events are free and open to all. There are no age or residency requirements. No ...
ICICI Bank net profit increased by 25% to Rs 6,194 crore
ICICI Bank net profit increased by 25% to Rs 6,194 crore
Non-interest income, excluding treasury income, increased by 25 per cent year-on-year to Rs 4,899 crore ($659 million) in Q3 of 2021-22 from Rs 3,921 crore ...
Intel is planning a $20 billion chip factory in Ohio
Intel is planning a $20 billion chip factory in Ohio
“Our expectation is that this becomes the largest silicon manufacturing location on the planet,” Intel CEO Pat Gelsinger told Time. The construction will ...
U of M fraternity raises money for chef’s knee surgery
U of M fraternity raises money for chef’s knee surgery
Sign up: Subscribe to our BREAKING NEWS newsletters “He also loves Lodge with all his heart, taking time out of his day to sometimes surprise us with free ...
Show next
We will be happy to hear your thoughts

Leave a reply

Compsmag - Latest News In Tech and Business
Logo